Global Postmenopausal Vaginal Atrophy Drugs Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Postmenopausal Vaginal Atrophy Drugs market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Postmenopausal vaginal atrophy (PVA) is the type of condition of vaginal wall thinning the reduced level of estrogen causes that. The changes in the genitourinary tract arising from a hypoestrogenic state includes decreased vaginal vascularization, reduced vaginal lubrication, thinning of the vaginal epithelium. The pH level continuously increases and loss of lactobacilli microflora allows opportunistic colonization by pathogenic bacteria can produce infection.
This report is a detailed and comprehensive analysis for global Postmenopausal Vaginal Atrophy Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Postmenopausal Vaginal Atrophy Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Postmenopausal Vaginal Atrophy Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Postmenopausal Vaginal Atrophy Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Postmenopausal Vaginal Atrophy Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Postmenopausal Vaginal Atrophy Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Postmenopausal Vaginal Atrophy Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc, Mylan NV, Novartis AG, Hikma Pharmaceuticals plc and Aurobindo Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Postmenopausal Vaginal Atrophy Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Postmenopausal Vaginal Atrophy Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Postmenopausal Vaginal Atrophy Drugs, with price, sales, revenue and global market share of Postmenopausal Vaginal Atrophy Drugs from 2018 to 2023.
Chapter 3, the Postmenopausal Vaginal Atrophy Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Postmenopausal Vaginal Atrophy Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Postmenopausal Vaginal Atrophy Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Postmenopausal Vaginal Atrophy Drugs.
Chapter 14 and 15, to describe Postmenopausal Vaginal Atrophy Drugs sales channel, distributors, customers, research findings and conclusion.
Postmenopausal vaginal atrophy (PVA) is the type of condition of vaginal wall thinning the reduced level of estrogen causes that. The changes in the genitourinary tract arising from a hypoestrogenic state includes decreased vaginal vascularization, reduced vaginal lubrication, thinning of the vaginal epithelium. The pH level continuously increases and loss of lactobacilli microflora allows opportunistic colonization by pathogenic bacteria can produce infection.
This report is a detailed and comprehensive analysis for global Postmenopausal Vaginal Atrophy Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Postmenopausal Vaginal Atrophy Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Postmenopausal Vaginal Atrophy Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Postmenopausal Vaginal Atrophy Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Postmenopausal Vaginal Atrophy Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Postmenopausal Vaginal Atrophy Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Postmenopausal Vaginal Atrophy Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc, Mylan NV, Novartis AG, Hikma Pharmaceuticals plc and Aurobindo Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Postmenopausal Vaginal Atrophy Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Topical Estrogen
- Oral Estrogen
- Other
- Online Pharmacy
- Hospital Pharmacy
- Pfizer Inc
- Mylan NV
- Novartis AG
- Hikma Pharmaceuticals plc
- Aurobindo Pharma
- AbbVie Inc
- Melinta Therapeutics, Inc
- Bristol-Myers Squibb Company
- GSK plc
- Bayer AG
- Lupin
- Perrigo Company plc
- Bionovo, Inc
- TherapeuticsMD, Inc
- Endoceutics, Inc
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Postmenopausal Vaginal Atrophy Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Postmenopausal Vaginal Atrophy Drugs, with price, sales, revenue and global market share of Postmenopausal Vaginal Atrophy Drugs from 2018 to 2023.
Chapter 3, the Postmenopausal Vaginal Atrophy Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Postmenopausal Vaginal Atrophy Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Postmenopausal Vaginal Atrophy Drugs market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Postmenopausal Vaginal Atrophy Drugs.
Chapter 14 and 15, to describe Postmenopausal Vaginal Atrophy Drugs sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Postmenopausal Vaginal Atrophy Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Topical Estrogen
1.3.3 Oral Estrogen
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Online Pharmacy
1.4.3 Hospital Pharmacy
1.5 Global Postmenopausal Vaginal Atrophy Drugs Market Size & Forecast
1.5.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity (2018-2029)
1.5.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Pfizer Inc
2.1.1 Pfizer Inc Details
2.1.2 Pfizer Inc Major Business
2.1.3 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.1.4 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer Inc Recent Developments/Updates
2.2 Mylan NV
2.2.1 Mylan NV Details
2.2.2 Mylan NV Major Business
2.2.3 Mylan NV Postmenopausal Vaginal Atrophy Drugs Product and Services
2.2.4 Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Mylan NV Recent Developments/Updates
2.3 Novartis AG
2.3.1 Novartis AG Details
2.3.2 Novartis AG Major Business
2.3.3 Novartis AG Postmenopausal Vaginal Atrophy Drugs Product and Services
2.3.4 Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Novartis AG Recent Developments/Updates
2.4 Hikma Pharmaceuticals plc
2.4.1 Hikma Pharmaceuticals plc Details
2.4.2 Hikma Pharmaceuticals plc Major Business
2.4.3 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.4.4 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Hikma Pharmaceuticals plc Recent Developments/Updates
2.5 Aurobindo Pharma
2.5.1 Aurobindo Pharma Details
2.5.2 Aurobindo Pharma Major Business
2.5.3 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product and Services
2.5.4 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Aurobindo Pharma Recent Developments/Updates
2.6 AbbVie Inc
2.6.1 AbbVie Inc Details
2.6.2 AbbVie Inc Major Business
2.6.3 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.6.4 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 AbbVie Inc Recent Developments/Updates
2.7 Melinta Therapeutics, Inc
2.7.1 Melinta Therapeutics, Inc Details
2.7.2 Melinta Therapeutics, Inc Major Business
2.7.3 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.7.4 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Melinta Therapeutics, Inc Recent Developments/Updates
2.8 Bristol-Myers Squibb Company
2.8.1 Bristol-Myers Squibb Company Details
2.8.2 Bristol-Myers Squibb Company Major Business
2.8.3 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product and Services
2.8.4 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Bristol-Myers Squibb Company Recent Developments/Updates
2.9 GSK plc
2.9.1 GSK plc Details
2.9.2 GSK plc Major Business
2.9.3 GSK plc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.9.4 GSK plc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 GSK plc Recent Developments/Updates
2.10 Bayer AG
2.10.1 Bayer AG Details
2.10.2 Bayer AG Major Business
2.10.3 Bayer AG Postmenopausal Vaginal Atrophy Drugs Product and Services
2.10.4 Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Bayer AG Recent Developments/Updates
2.11 Lupin
2.11.1 Lupin Details
2.11.2 Lupin Major Business
2.11.3 Lupin Postmenopausal Vaginal Atrophy Drugs Product and Services
2.11.4 Lupin Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Lupin Recent Developments/Updates
2.12 Perrigo Company plc
2.12.1 Perrigo Company plc Details
2.12.2 Perrigo Company plc Major Business
2.12.3 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.12.4 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Perrigo Company plc Recent Developments/Updates
2.13 Bionovo, Inc
2.13.1 Bionovo, Inc Details
2.13.2 Bionovo, Inc Major Business
2.13.3 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.13.4 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Bionovo, Inc Recent Developments/Updates
2.14 TherapeuticsMD, Inc
2.14.1 TherapeuticsMD, Inc Details
2.14.2 TherapeuticsMD, Inc Major Business
2.14.3 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.14.4 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 TherapeuticsMD, Inc Recent Developments/Updates
2.15 Endoceutics, Inc
2.15.1 Endoceutics, Inc Details
2.15.2 Endoceutics, Inc Major Business
2.15.3 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.15.4 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Endoceutics, Inc Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: POSTMENOPAUSAL VAGINAL ATROPHY DRUGS BY MANUFACTURER
3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Postmenopausal Vaginal Atrophy Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Postmenopausal Vaginal Atrophy Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Postmenopausal Vaginal Atrophy Drugs Manufacturer Market Share in 2022
3.5 Postmenopausal Vaginal Atrophy Drugs Market: Overall Company Footprint Analysis
3.5.1 Postmenopausal Vaginal Atrophy Drugs Market: Region Footprint
3.5.2 Postmenopausal Vaginal Atrophy Drugs Market: Company Product Type Footprint
3.5.3 Postmenopausal Vaginal Atrophy Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2018-2029)
4.2 North America Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029)
4.3 Europe Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029)
4.5 South America Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2029)
5.2 Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Type (2018-2029)
5.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2029)
6.2 Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Application (2018-2029)
6.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2029)
7.2 North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2029)
7.3 North America Postmenopausal Vaginal Atrophy Drugs Market Size by Country
7.3.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Size by Country
8.3.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size by Region
9.3.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2029)
10.2 South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2029)
10.3 South America Postmenopausal Vaginal Atrophy Drugs Market Size by Country
10.3.1 South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Market Size by Country
11.3.1 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Postmenopausal Vaginal Atrophy Drugs Market Drivers
12.2 Postmenopausal Vaginal Atrophy Drugs Market Restraints
12.3 Postmenopausal Vaginal Atrophy Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Postmenopausal Vaginal Atrophy Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Postmenopausal Vaginal Atrophy Drugs
13.3 Postmenopausal Vaginal Atrophy Drugs Production Process
13.4 Postmenopausal Vaginal Atrophy Drugs Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Postmenopausal Vaginal Atrophy Drugs Typical Distributors
14.3 Postmenopausal Vaginal Atrophy Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Postmenopausal Vaginal Atrophy Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Topical Estrogen
1.3.3 Oral Estrogen
1.3.4 Other
1.4 Market Analysis by Application
1.4.1 Overview: Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Online Pharmacy
1.4.3 Hospital Pharmacy
1.5 Global Postmenopausal Vaginal Atrophy Drugs Market Size & Forecast
1.5.1 Global Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity (2018-2029)
1.5.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Pfizer Inc
2.1.1 Pfizer Inc Details
2.1.2 Pfizer Inc Major Business
2.1.3 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.1.4 Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer Inc Recent Developments/Updates
2.2 Mylan NV
2.2.1 Mylan NV Details
2.2.2 Mylan NV Major Business
2.2.3 Mylan NV Postmenopausal Vaginal Atrophy Drugs Product and Services
2.2.4 Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Mylan NV Recent Developments/Updates
2.3 Novartis AG
2.3.1 Novartis AG Details
2.3.2 Novartis AG Major Business
2.3.3 Novartis AG Postmenopausal Vaginal Atrophy Drugs Product and Services
2.3.4 Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Novartis AG Recent Developments/Updates
2.4 Hikma Pharmaceuticals plc
2.4.1 Hikma Pharmaceuticals plc Details
2.4.2 Hikma Pharmaceuticals plc Major Business
2.4.3 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.4.4 Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Hikma Pharmaceuticals plc Recent Developments/Updates
2.5 Aurobindo Pharma
2.5.1 Aurobindo Pharma Details
2.5.2 Aurobindo Pharma Major Business
2.5.3 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product and Services
2.5.4 Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Aurobindo Pharma Recent Developments/Updates
2.6 AbbVie Inc
2.6.1 AbbVie Inc Details
2.6.2 AbbVie Inc Major Business
2.6.3 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.6.4 AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 AbbVie Inc Recent Developments/Updates
2.7 Melinta Therapeutics, Inc
2.7.1 Melinta Therapeutics, Inc Details
2.7.2 Melinta Therapeutics, Inc Major Business
2.7.3 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.7.4 Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Melinta Therapeutics, Inc Recent Developments/Updates
2.8 Bristol-Myers Squibb Company
2.8.1 Bristol-Myers Squibb Company Details
2.8.2 Bristol-Myers Squibb Company Major Business
2.8.3 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product and Services
2.8.4 Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Bristol-Myers Squibb Company Recent Developments/Updates
2.9 GSK plc
2.9.1 GSK plc Details
2.9.2 GSK plc Major Business
2.9.3 GSK plc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.9.4 GSK plc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 GSK plc Recent Developments/Updates
2.10 Bayer AG
2.10.1 Bayer AG Details
2.10.2 Bayer AG Major Business
2.10.3 Bayer AG Postmenopausal Vaginal Atrophy Drugs Product and Services
2.10.4 Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Bayer AG Recent Developments/Updates
2.11 Lupin
2.11.1 Lupin Details
2.11.2 Lupin Major Business
2.11.3 Lupin Postmenopausal Vaginal Atrophy Drugs Product and Services
2.11.4 Lupin Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Lupin Recent Developments/Updates
2.12 Perrigo Company plc
2.12.1 Perrigo Company plc Details
2.12.2 Perrigo Company plc Major Business
2.12.3 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.12.4 Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Perrigo Company plc Recent Developments/Updates
2.13 Bionovo, Inc
2.13.1 Bionovo, Inc Details
2.13.2 Bionovo, Inc Major Business
2.13.3 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.13.4 Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Bionovo, Inc Recent Developments/Updates
2.14 TherapeuticsMD, Inc
2.14.1 TherapeuticsMD, Inc Details
2.14.2 TherapeuticsMD, Inc Major Business
2.14.3 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.14.4 TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 TherapeuticsMD, Inc Recent Developments/Updates
2.15 Endoceutics, Inc
2.15.1 Endoceutics, Inc Details
2.15.2 Endoceutics, Inc Major Business
2.15.3 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
2.15.4 Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Endoceutics, Inc Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: POSTMENOPAUSAL VAGINAL ATROPHY DRUGS BY MANUFACTURER
3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Manufacturer (2018-2023)
3.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturer (2018-2023)
3.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Postmenopausal Vaginal Atrophy Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Postmenopausal Vaginal Atrophy Drugs Manufacturer Market Share in 2022
3.4.2 Top 6 Postmenopausal Vaginal Atrophy Drugs Manufacturer Market Share in 2022
3.5 Postmenopausal Vaginal Atrophy Drugs Market: Overall Company Footprint Analysis
3.5.1 Postmenopausal Vaginal Atrophy Drugs Market: Region Footprint
3.5.2 Postmenopausal Vaginal Atrophy Drugs Market: Company Product Type Footprint
3.5.3 Postmenopausal Vaginal Atrophy Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2018-2029)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2018-2029)
4.1.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2018-2029)
4.2 North America Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029)
4.3 Europe Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029)
4.4 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029)
4.5 South America Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029)
4.6 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2029)
5.2 Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Type (2018-2029)
5.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2029)
6.2 Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Application (2018-2029)
6.3 Global Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2029)
7.2 North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2029)
7.3 North America Postmenopausal Vaginal Atrophy Drugs Market Size by Country
7.3.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2029)
7.3.2 North America Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2029)
8.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2029)
8.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Size by Country
8.3.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2029)
8.3.2 Europe Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size by Region
9.3.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2029)
10.2 South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2029)
10.3 South America Postmenopausal Vaginal Atrophy Drugs Market Size by Country
10.3.1 South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2029)
10.3.2 South America Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Market Size by Country
11.3.1 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 Postmenopausal Vaginal Atrophy Drugs Market Drivers
12.2 Postmenopausal Vaginal Atrophy Drugs Market Restraints
12.3 Postmenopausal Vaginal Atrophy Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Postmenopausal Vaginal Atrophy Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Postmenopausal Vaginal Atrophy Drugs
13.3 Postmenopausal Vaginal Atrophy Drugs Production Process
13.4 Postmenopausal Vaginal Atrophy Drugs Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Postmenopausal Vaginal Atrophy Drugs Typical Distributors
14.3 Postmenopausal Vaginal Atrophy Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Inc Major Business
Table 5. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 6. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Pfizer Inc Recent Developments/Updates
Table 8. Mylan NV Basic Information, Manufacturing Base and Competitors
Table 9. Mylan NV Major Business
Table 10. Mylan NV Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 11. Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Mylan NV Recent Developments/Updates
Table 13. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 14. Novartis AG Major Business
Table 15. Novartis AG Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 16. Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Novartis AG Recent Developments/Updates
Table 18. Hikma Pharmaceuticals plc Basic Information, Manufacturing Base and Competitors
Table 19. Hikma Pharmaceuticals plc Major Business
Table 20. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 21. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Hikma Pharmaceuticals plc Recent Developments/Updates
Table 23. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
Table 24. Aurobindo Pharma Major Business
Table 25. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 26. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Aurobindo Pharma Recent Developments/Updates
Table 28. AbbVie Inc Basic Information, Manufacturing Base and Competitors
Table 29. AbbVie Inc Major Business
Table 30. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 31. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. AbbVie Inc Recent Developments/Updates
Table 33. Melinta Therapeutics, Inc Basic Information, Manufacturing Base and Competitors
Table 34. Melinta Therapeutics, Inc Major Business
Table 35. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 36. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Melinta Therapeutics, Inc Recent Developments/Updates
Table 38. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 39. Bristol-Myers Squibb Company Major Business
Table 40. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 41. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Bristol-Myers Squibb Company Recent Developments/Updates
Table 43. GSK plc Basic Information, Manufacturing Base and Competitors
Table 44. GSK plc Major Business
Table 45. GSK plc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 46. GSK plc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. GSK plc Recent Developments/Updates
Table 48. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 49. Bayer AG Major Business
Table 50. Bayer AG Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 51. Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Bayer AG Recent Developments/Updates
Table 53. Lupin Basic Information, Manufacturing Base and Competitors
Table 54. Lupin Major Business
Table 55. Lupin Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 56. Lupin Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Lupin Recent Developments/Updates
Table 58. Perrigo Company plc Basic Information, Manufacturing Base and Competitors
Table 59. Perrigo Company plc Major Business
Table 60. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 61. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Perrigo Company plc Recent Developments/Updates
Table 63. Bionovo, Inc Basic Information, Manufacturing Base and Competitors
Table 64. Bionovo, Inc Major Business
Table 65. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 66. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Bionovo, Inc Recent Developments/Updates
Table 68. TherapeuticsMD, Inc Basic Information, Manufacturing Base and Competitors
Table 69. TherapeuticsMD, Inc Major Business
Table 70. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 71. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. TherapeuticsMD, Inc Recent Developments/Updates
Table 73. Endoceutics, Inc Basic Information, Manufacturing Base and Competitors
Table 74. Endoceutics, Inc Major Business
Table 75. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 76. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Endoceutics, Inc Recent Developments/Updates
Table 78. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 79. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 80. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 81. Market Position of Manufacturers in Postmenopausal Vaginal Atrophy Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 82. Head Office and Postmenopausal Vaginal Atrophy Drugs Production Site of Key Manufacturer
Table 83. Postmenopausal Vaginal Atrophy Drugs Market: Company Product Type Footprint
Table 84. Postmenopausal Vaginal Atrophy Drugs Market: Company Product Application Footprint
Table 85. Postmenopausal Vaginal Atrophy Drugs New Market Entrants and Barriers to Market Entry
Table 86. Postmenopausal Vaginal Atrophy Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 87. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 88. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 89. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 90. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 91. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 92. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 93. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 94. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 95. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 96. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 97. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 98. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 99. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 100. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 101. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 102. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 103. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 104. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 105. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 106. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 107. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 108. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 109. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 110. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 111. North America Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 112. North America Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 113. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 114. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 115. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 116. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 117. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 118. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 119. Europe Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 122. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 123. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 124. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 125. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 126. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 127. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 128. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 129. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 130. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 131. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 132. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 133. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 134. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 135. South America Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 136. South America Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 137. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 138. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 139. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 140. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 141. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 142. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 143. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 144. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 145. Postmenopausal Vaginal Atrophy Drugs Raw Material
Table 146. Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs Raw Materials
Table 147. Postmenopausal Vaginal Atrophy Drugs Typical Distributors
Table 148. Postmenopausal Vaginal Atrophy Drugs Typical Customers
Table 1. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Inc Major Business
Table 5. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 6. Pfizer Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Pfizer Inc Recent Developments/Updates
Table 8. Mylan NV Basic Information, Manufacturing Base and Competitors
Table 9. Mylan NV Major Business
Table 10. Mylan NV Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 11. Mylan NV Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Mylan NV Recent Developments/Updates
Table 13. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 14. Novartis AG Major Business
Table 15. Novartis AG Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 16. Novartis AG Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Novartis AG Recent Developments/Updates
Table 18. Hikma Pharmaceuticals plc Basic Information, Manufacturing Base and Competitors
Table 19. Hikma Pharmaceuticals plc Major Business
Table 20. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 21. Hikma Pharmaceuticals plc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Hikma Pharmaceuticals plc Recent Developments/Updates
Table 23. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
Table 24. Aurobindo Pharma Major Business
Table 25. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 26. Aurobindo Pharma Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Aurobindo Pharma Recent Developments/Updates
Table 28. AbbVie Inc Basic Information, Manufacturing Base and Competitors
Table 29. AbbVie Inc Major Business
Table 30. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 31. AbbVie Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. AbbVie Inc Recent Developments/Updates
Table 33. Melinta Therapeutics, Inc Basic Information, Manufacturing Base and Competitors
Table 34. Melinta Therapeutics, Inc Major Business
Table 35. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 36. Melinta Therapeutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Melinta Therapeutics, Inc Recent Developments/Updates
Table 38. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 39. Bristol-Myers Squibb Company Major Business
Table 40. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 41. Bristol-Myers Squibb Company Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Bristol-Myers Squibb Company Recent Developments/Updates
Table 43. GSK plc Basic Information, Manufacturing Base and Competitors
Table 44. GSK plc Major Business
Table 45. GSK plc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 46. GSK plc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. GSK plc Recent Developments/Updates
Table 48. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 49. Bayer AG Major Business
Table 50. Bayer AG Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 51. Bayer AG Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Bayer AG Recent Developments/Updates
Table 53. Lupin Basic Information, Manufacturing Base and Competitors
Table 54. Lupin Major Business
Table 55. Lupin Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 56. Lupin Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Lupin Recent Developments/Updates
Table 58. Perrigo Company plc Basic Information, Manufacturing Base and Competitors
Table 59. Perrigo Company plc Major Business
Table 60. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 61. Perrigo Company plc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Perrigo Company plc Recent Developments/Updates
Table 63. Bionovo, Inc Basic Information, Manufacturing Base and Competitors
Table 64. Bionovo, Inc Major Business
Table 65. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 66. Bionovo, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Bionovo, Inc Recent Developments/Updates
Table 68. TherapeuticsMD, Inc Basic Information, Manufacturing Base and Competitors
Table 69. TherapeuticsMD, Inc Major Business
Table 70. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 71. TherapeuticsMD, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. TherapeuticsMD, Inc Recent Developments/Updates
Table 73. Endoceutics, Inc Basic Information, Manufacturing Base and Competitors
Table 74. Endoceutics, Inc Major Business
Table 75. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Product and Services
Table 76. Endoceutics, Inc Postmenopausal Vaginal Atrophy Drugs Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Endoceutics, Inc Recent Developments/Updates
Table 78. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 79. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturer (2018-2023) & (USD Million)
Table 80. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 81. Market Position of Manufacturers in Postmenopausal Vaginal Atrophy Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 82. Head Office and Postmenopausal Vaginal Atrophy Drugs Production Site of Key Manufacturer
Table 83. Postmenopausal Vaginal Atrophy Drugs Market: Company Product Type Footprint
Table 84. Postmenopausal Vaginal Atrophy Drugs Market: Company Product Application Footprint
Table 85. Postmenopausal Vaginal Atrophy Drugs New Market Entrants and Barriers to Market Entry
Table 86. Postmenopausal Vaginal Atrophy Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 87. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 88. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 89. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 90. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 91. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2018-2023) & (US$/Unit)
Table 92. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Region (2024-2029) & (US$/Unit)
Table 93. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 94. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 95. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Type (2018-2023) & (USD Million)
Table 96. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Type (2024-2029) & (USD Million)
Table 97. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2018-2023) & (US$/Unit)
Table 98. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2024-2029) & (US$/Unit)
Table 99. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 100. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 101. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Application (2018-2023) & (USD Million)
Table 102. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Application (2024-2029) & (USD Million)
Table 103. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2018-2023) & (US$/Unit)
Table 104. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2024-2029) & (US$/Unit)
Table 105. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 106. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 107. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 108. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 109. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 110. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 111. North America Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 112. North America Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 113. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 114. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 115. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 116. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 117. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 118. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 119. Europe Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 122. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 123. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 124. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 125. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 126. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 127. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 128. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 129. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 130. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 131. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 132. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 133. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2018-2023) & (K Units)
Table 134. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Country (2024-2029) & (K Units)
Table 135. South America Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2018-2023) & (USD Million)
Table 136. South America Postmenopausal Vaginal Atrophy Drugs Consumption Value by Country (2024-2029) & (USD Million)
Table 137. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2018-2023) & (K Units)
Table 138. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Type (2024-2029) & (K Units)
Table 139. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2018-2023) & (K Units)
Table 140. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Application (2024-2029) & (K Units)
Table 141. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2018-2023) & (K Units)
Table 142. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity by Region (2024-2029) & (K Units)
Table 143. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2018-2023) & (USD Million)
Table 144. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value by Region (2024-2029) & (USD Million)
Table 145. Postmenopausal Vaginal Atrophy Drugs Raw Material
Table 146. Key Manufacturers of Postmenopausal Vaginal Atrophy Drugs Raw Materials
Table 147. Postmenopausal Vaginal Atrophy Drugs Typical Distributors
Table 148. Postmenopausal Vaginal Atrophy Drugs Typical Customers
LIST OF FIGURES
Figure 1. Postmenopausal Vaginal Atrophy Drugs Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Type in 2022
Figure 4. Topical Estrogen Examples
Figure 5. Oral Estrogen Examples
Figure 6. Other Examples
Figure 7. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Application in 2022
Figure 9. Online Pharmacy Examples
Figure 10. Hospital Pharmacy Examples
Figure 11. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity (2018-2029) & (K Units)
Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Average Price (2018-2029) & (US$/Unit)
Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of Postmenopausal Vaginal Atrophy Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 Postmenopausal Vaginal Atrophy Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 Postmenopausal Vaginal Atrophy Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Region (2018-2029)
Figure 22. North America Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Type (2018-2029)
Figure 29. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 30. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Application (2018-2029)
Figure 32. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 33. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Country (2018-2029)
Figure 37. United States Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Region (2018-2029)
Figure 53. China Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Postmenopausal Vaginal Atrophy Drugs Market Drivers
Figure 74. Postmenopausal Vaginal Atrophy Drugs Market Restraints
Figure 75. Postmenopausal Vaginal Atrophy Drugs Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Postmenopausal Vaginal Atrophy Drugs in 2022
Figure 78. Manufacturing Process Analysis of Postmenopausal Vaginal Atrophy Drugs
Figure 79. Postmenopausal Vaginal Atrophy Drugs Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
Figure 1. Postmenopausal Vaginal Atrophy Drugs Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Type in 2022
Figure 4. Topical Estrogen Examples
Figure 5. Oral Estrogen Examples
Figure 6. Other Examples
Figure 7. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Application in 2022
Figure 9. Online Pharmacy Examples
Figure 10. Hospital Pharmacy Examples
Figure 11. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity (2018-2029) & (K Units)
Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Average Price (2018-2029) & (US$/Unit)
Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of Postmenopausal Vaginal Atrophy Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 Postmenopausal Vaginal Atrophy Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 Postmenopausal Vaginal Atrophy Drugs Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Region (2018-2029)
Figure 22. North America Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 25. South America Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value (2018-2029) & (USD Million)
Figure 27. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Type (2018-2029)
Figure 29. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Type (2018-2029) & (US$/Unit)
Figure 30. Global Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Application (2018-2029)
Figure 32. Global Postmenopausal Vaginal Atrophy Drugs Average Price by Application (2018-2029) & (US$/Unit)
Figure 33. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Country (2018-2029)
Figure 37. United States Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Region (2018-2029)
Figure 53. China Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa Postmenopausal Vaginal Atrophy Drugs Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. Postmenopausal Vaginal Atrophy Drugs Market Drivers
Figure 74. Postmenopausal Vaginal Atrophy Drugs Market Restraints
Figure 75. Postmenopausal Vaginal Atrophy Drugs Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of Postmenopausal Vaginal Atrophy Drugs in 2022
Figure 78. Manufacturing Process Analysis of Postmenopausal Vaginal Atrophy Drugs
Figure 79. Postmenopausal Vaginal Atrophy Drugs Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
